• In late May 2026, CVS Health announced past updates to its CVS Caremark commercial formularies, reintroducing Zepbound (tirzepatide) as a preferred GLP-1 option from October 1, 2026, and lifting the new-to-market block on the oral GLP-1 Foundayo (orforglipron) for plans that approve coverage.
• By broadening access to GLP-1 weight management drugs while emphasizing affordability for plan sponsors, CVS Health is reinforcing its role as a pharmacy benefits manager focused on cost control and clinically guided access to high-demand therapies.
• We’ll now examine how this expansion of GLP-1 coverage through CVS Caremark could reshape CVS Health’s broader investment narrative and long-term positioning.

Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

CVS Health Investment Narrative Recap

To own CVS Health, you have to believe in its integrated model across insurance, pharmacy benefits and retail care, and its ability to protect margins despite reimbursement and medical cost pressures. The Caremark decision to broaden GLP-1 access looks directionally supportive for its pharmacy benefits narrative, but the near term earnings story still appears most exposed to elevated medical costs and reimbursement pressure, so the news does not materially change the key catalyst or biggest risk right now.

Among recent announcements, CVS Health’s plan to expand biosimilar use across high cost specialty drugs from July 2026 feels especially relevant, as it complements the GLP-1 moves by underlining a consistent focus on formulary management and affordability. Together, these updates sit at the heart of what investors are watching most closely: whether Caremark can keep controlling drug spend for plan sponsors while supporting CVS Health’s margin resilience.

Yet, for investors, the real concern may be how rising medical costs and reimbursement pressure could ultimately affect...

CVS Health's narrative projects $452.9 billion revenue and $10.6 billion earnings by 2029.

Uncover how CVS Health's forecasts yield a $101.58 fair value, a 12% upside to its current price.

Exploring Other Perspectives

Five members of the Simply Wall St Community currently see CVS Health’s fair value between about US$101.6 and US$302.6, reflecting very different expectations. As you weigh those views, remember that persistent reimbursement pressure and elevated medical costs could be just as important to the company’s future as any individual growth initiative.

Explore 5 other fair value estimates on CVS Health - why the stock might be worth over 3x more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your CVS Health research is our analysis highlighting 2 key rewards and 5 important warning signs that could impact your investment decision.
• Our free CVS Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate CVS Health's overall financial health at a glance.

Seeking Other Investments?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.
• Capitalize on the AI infrastructure supercycle with our selection of the 47 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.